Literature DB >> 7700640

Inhibition of CD4/p56lck signaling by a dominant negative mutant of the Shc adaptor protein.

C T Baldari1, G Pelicci, M M Di Somma, E Milia, S Giuli, P G Pelicci, J L Telford.   

Abstract

T-cell antigen receptor stimulation results in phosphorylation of the SH2 containing Shc proteins and recruitment of the Grb2/mSos complex suggesting that Shc proteins are involved in transducing T-cell activating signals to Ras. We have measured the effects of the isolated Shc-SH2 domain and the dominant negative RasN17 protein on activation of the T-cell specific transcription factor NF-AT. The isolated Shc-SH2 domain was designed to compete with endogenous Shc binding to upstream tyrosine phosphorylated proteins and to interfere with coupling to regulators of Ras activation. We have demonstrated that both the Shc-SH2 domain and the RasN17 protein significantly inhibited NF-AT activation by the CD4 coreceptor and the CD4 associated tyrosine kinase p56lck. In contrast, only the RasN17 protein reduced NF-AT activation by the TCR/CD3 complex. Furthermore, tyrosine kinase activity and p56lck protein were found in complexes immunoprecipitated with Shc specific antisera after CD4 triggering but not after CD3 triggering. These results indicate that both CD4 and CD3 signal to Ras and that this signaling is mediated by independent pathways of activation of the Shc adaptor protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7700640

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway.

Authors:  E Migliaccio; S Mele; A E Salcini; G Pelicci; K M Lai; G Superti-Furga; T Pawson; P P Di Fiore; L Lanfrancone; P G Pelicci
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

2.  Characterization of the roles of SH2 domain-containing proteins in T-lymphocyte activation by using dominant negative SH2 domains.

Authors:  J P Northrop; M J Pustelnik; A T Lu; J R Grove
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation.

Authors:  L V Lotti; L Lanfrancone; E Migliaccio; C Zompetta; G Pelicci; A E Salcini; B Falini; P G Pelicci; M R Torrisi
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

4.  Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc.

Authors:  O Kranenburg; I Verlaan; P L Hordijk; W H Moolenaar
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

Review 5.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

6.  A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3.

Authors:  N Gotoh; A Tojo; M Shibuya
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

7.  The protein tyrosine kinase p56lck is required for triggering NF-kappaB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4.

Authors:  L Briant; V Robert-Hebmann; C Acquaviva; A Pelchen-Matthews; M Marsh; C Devaux
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Polyomavirus large T antigen induces alterations in cytoplasmic signalling pathways involving Shc activation.

Authors:  V Gottifredi; G Pelicci; E Munarriz; R Maione; P G Pelicci; P Amati
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells.

Authors:  R Galandrini; G Palmieri; M Piccoli; L Frati; A Santoni
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.